Ligand Dusts Off Lasofoxifene, Signs 2 Deals for Pfizer Castoff
A few years after Ligand Pharmaceuticals Inc. regained the rights to its selective estrogen receptor modulator (SERM) lasofoxifene from Pfizer Inc., the company has dusted off the osteoporosis drug and found new parties interested in moving the molecule forward.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST